Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor vaccine + toll-like receptor agonists
- Development stage
- Preclinical
- Lead developer
- Vaxine
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal, Subcutaneous, Intramuscular, Intratumoral, Intravenous, Intranasal, Oral, Intradermal, Transdermal
01
Overview
Autologous tumor vaccine + toll-like receptor agonists is a personalized cancer immunotherapy candidate developed by Vaxine. This therapeutic approach utilizes patient-derived tumor antigens (autologous) to ensure the immune response is specifically targeted against the individual's unique cancer profile. The vaccine is combined with toll-like receptor (TLR) agonists and Vaxine's proprietary Advax adjuvant technology. The mechanism of action involves the TLR agonists stimulating the innate immune system to provide necessary co-stimulatory signals, which facilitates the priming and expansion of tumor-specific adaptive T-cell responses. This dual-action strategy is designed to overcome tumor-induced immune suppression and generate a potent anti-tumor effect. The program is currently in the preclinical stage of development.
- Other names
- autologous tumor vaccine with TLR agonistsVaxine cancer immunotherapy
02
Targets
TLR2 (Toll-like Receptor 2)TLR3 (Toll-like receptor 3)TLR4 (Toll-like receptor 4)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)TLR9 (Toll-like receptor 9)ATA (Tumor antigens from autologous tumor cells/lysate)
Beyond the preview
Go deeper on autologous tumor vaccine + toll-like receptor agonists.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor vaccine + toll-like receptor agonists.